About Jiksak Bioengineering
Jiksak Bioengineering is a Healthcare company based in Kawasaki (Japan) founded in 2017. Developer of nerve tissue products for neurodegenerative diseases. Jiksak Bioengineering has raised $5.81 million across 1 funding round. Its chief executive, as recorded, is Jiro Kawada. Jiksak Bioengineering offers products and services including Nerve Organoidâ„¢ and Engineered Human Synapses. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is Jiksak Bioengineering, Inc.
Company details
Jiksak Bioengineering was founded in 2017 in Kawasaki, Japan, within the bioengineering sector. Focus is placed on creating nerve organoid chips from human iPS cell-derived neural tissue, enabling pathological analysis of nerve structures. A drug targeting the neuromuscular junction is also developed for treating neurodegenerative conditions, including Parkinsons disease. Operations center on advancing therapies for such diseases through tissue-based innovations.
- Headquarters Kawasaki, Japan
- SectorsHealthcare
- Website jiksak.co.jp
- Social LinkedIn
- Legal Name Jiksak Bioengineering, Inc.
- Total Equity Funding$5.81M (USD)
in 1 rounds
- Latest Funding Round$5.81M (USD), Series B
Aug 2022
Products & Services of Jiksak Bioengineering
Jiksak Bioengineering offers a comprehensive portfolio of products and services, including Nerve Organoid™ and Engineered Human Synapses.
Technology for developing safer nerve conduits and regeneration.
Innovation for neuromuscular disease therapies and function restoration.
Funding Insights of Jiksak Bioengineering
Jiksak Bioengineering has successfully raised a total of $5.81M through 1 strategic funding round. The most recent funding activity was a Series B round of $5.81 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.81M
- Total Rounds 1
- Last Round Series B — $5.81M
- First Round $5.81M
(Aug 2022)
All 1 funding rounds of Jiksak Bioengineering with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $5.81M | Series B | – | – | – |
People of Jiksak Bioengineering
3 people are tracked at Jiksak Bioengineering (3 in leadership).
| Name | Role | Group |
|---|---|---|
Jiro Kawada | CEO | Leadership |
Nori Yumoto | Co-Chief Executive Officer | Leadership |
Takahara Hiroumi | Chief Financial Officer | Leadership |
Complete people profiles for Jiksak Bioengineering
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Jiksak Bioengineering
2 dated milestones of Jiksak Bioengineering across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Jiksak Bioengineering is founded.
- Funding First funding round of $5.8M.
Web traffic of Jiksak Bioengineering
The website of Jiksak Bioengineering (jiksak.co.jp) receives about 3.9K visits a month.
- Monthly visits3.9K
▲ 27.4% vs previous month
Websites whose visitors overlap most with Jiksak Bioengineering. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
molmir.co.jp | molmir.co.jp | 100% | #12,363,712 | – | |
zeonoss.com | zeonoss.com | 87% | #8,787,337 | – | |
news.jsrlifesciences.com | news.jsrlifesciences.com | 82% | – | ||
taskyoda.com | taskyoda.com | 76% | #13,034,857 | – | |
| anri.vc | 73% | #1,835,198 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Jiksak Bioengineering
Jiksak Bioengineering was founded in 2017 and raised its 1st funding round 5 years after it was founded.
Jiksak Bioengineering is headquartered in Kawasaki, Japan. It is registered at Kawasaki, Kanagawa, Japan.
Jiro Kawada is the CEO of Jiksak Bioengineering, as recorded in our data.
Jiksak Bioengineering is a funded company, having raised a total of $5.81M across 1 funding round to date. The company's 1st funding round was a Series B of $5.81M, raised on Aug 2022.
Jiksak Bioengineering was founded in 2017 in Kawasaki, Japan, within the bioengineering sector. Focus is placed on creating nerve organoid chips from human iPS cell-derived neural tissue, enabling pathological analysis of nerve structures. A drug targeting the neuromuscular junction is also developed for treating neurodegenerative conditions, including Parkinsons disease. Operations center on advancing therapies for such diseases through tissue-based innovations.
Jiksak Bioengineering offers Nerve Organoidâ„¢ and Engineered Human Synapses.
Jiksak Bioengineering operates through Jiksak Bioengineering, Inc..